Valerie Morisset, Executive Vice President, Research & Development and Chief Scientific Officer at Eliem Therapeutics Inc (ELYM, Financial), sold 129,206 shares of the company on July 22, 2024. The transaction was reported in a recent SEC Filing. Following this sale, the insider now owns 31,317 shares of Eliem Therapeutics Inc.
Eliem Therapeutics Inc is focused on developing therapies for pain, epilepsy, and depression. The company aims to address the significant unmet medical needs in these areas through advanced scientific and clinical research.
Over the past year, the insider has sold a total of 481,639 shares and has not made any purchases. The recent sale is part of a broader trend observed at Eliem Therapeutics Inc, where there have been 8 insider sells and only 1 insider buy over the past year.
On the date of the latest transaction, shares of Eliem Therapeutics Inc were trading at $7.65, resulting in a market cap of approximately $596.394 million.
For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors and analysts can visit the respective links.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
